{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:15:33Z","timestamp":1791274533977,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1124\/jpet.111.187443","type":"journal-article","created":{"date-parts":[[2011,11,17]],"date-time":"2011-11-17T12:39:39Z","timestamp":1321533579000},"page":"404-421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"title":["The Metabotropic Glutamate Receptor 4-Positive Allosteric Modulator VU0364770 Produces Efficacy Alone and in Combination with l-DOPA or an Adenosine 2A Antagonist in Preclinical Rodent Models of Parkinson\u2019s Disease"],"prefix":"10.1016","volume":"340","author":[{"given":"Carrie K.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bubser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Analisa D.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Dickerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Turle-Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Amalric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna L.","family":"Blobaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Bridges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D.","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyawan","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren W.","family":"Engers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Bode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Scott","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig W.","family":"Lindsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey R.","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Jeffrey","family":"Conn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen M.","family":"Niswender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.111.187443_bib1","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/j.1460-9568.1995.tb01085.x","article-title":"Complex deficits on reaction time performance following bilateral intrastriatal 6-OHDA infusion in the rat","volume":"7","author":"Amalric","year":"1995","journal-title":"Eur J Neurosci"},{"key":"10.1124\/jpet.111.187443_bib2","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1096\/fj.09-131789","article-title":"Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism","volume":"23","author":"Beurrier","year":"2009","journal-title":"FASEB J"},{"key":"10.1124\/jpet.111.187443_bib3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/(SICI)1096-9861(19990428)407:1<33::AID-CNE3>3.0.CO;2-G","article-title":"Immunohistochemical localization of subtype 4a metabotropic glutamate receptors in the rat and mouse basal ganglia","volume":"407","author":"Bradley","year":"1999","journal-title":"J Comp Neurol"},{"key":"10.1124\/jpet.111.187443_bib4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF01252507","article-title":"Modification of dopamine and norepinephrine metabolism in the rat brain by monoamine oxidase inhibitors","volume":"70","author":"Buu","year":"1987","journal-title":"J Neural Transm"},{"key":"10.1124\/jpet.111.187443_bib5","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nrn1763","article-title":"Metabotropic glutamate receptors in the basal ganglia motor circuit","volume":"6","author":"Conn","year":"2005","journal-title":"Nat Rev Neurosci"},{"key":"10.1124\/jpet.111.187443_bib6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0306-4522(01)00591-7","article-title":"Distribution and synaptic localisation of the metabotropic glutamate receptor 4 (mGluR4) in the rodent CNS","volume":"110","author":"Corti","year":"2002","journal-title":"Neuroscience"},{"key":"10.1124\/jpet.111.187443_bib7","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1021\/jm9005065","article-title":"Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs)","volume":"52","author":"Engers","year":"2009","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.111.187443_bib8","first-page":"387","article-title":"Pathologie der paralysis agitans und des postenzephalitischen Parkinsonismus","volume":"48","author":"Hassler","year":"1938","journal-title":"J Psychol Neurol"},{"key":"10.1124\/jpet.111.187443_bib9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1474-4422(11)70012-6","article-title":"Preladenant in patients with Parkinson\u2019s disease and motor fluctuations: a phase 2, double-blind, randomised trial","volume":"10","author":"Hauser","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1124\/jpet.111.187443_bib10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/1096-9861(20010312)431:3<331::AID-CNE1074>3.0.CO;2-W","article-title":"Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum","volume":"431","author":"Hettinger","year":"2001","journal-title":"J Comp Neurol"},{"key":"10.1124\/jpet.111.187443_bib11","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.expneurol.2010.07.011","article-title":"Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders","volume":"225","author":"Hodgson","year":"2010","journal-title":"Exp Neurol"},{"key":"10.1124\/jpet.111.187443_bib12","series-title":"Guide for the Care and Use of Laboratory Animals","year":"1996"},{"key":"10.1124\/jpet.111.187443_bib13","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","article-title":"Parkinson\u2019s disease: clinical features and diagnosis","volume":"79","author":"Jankovic","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1124\/jpet.111.187443_bib14","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1523\/JNEUROSCI.05-06-01513.1985","article-title":"Differential visualization of dopamine and norepinephrine uptake sites in rat brain using [3H]mazindol autoradiography","volume":"5","author":"Javitch","year":"1985","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.111.187443_bib15","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2174\/187152709789824606","article-title":"Glutamate receptors as therapeutic targets for Parkinson\u2019s disease","volume":"8","author":"Johnson","year":"2009","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1124\/jpet.111.187443_bib16","doi-asserted-by":"crossref","first-page":"6701","DOI":"10.1523\/JNEUROSCI.0299-07.2007","article-title":"Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson\u2019s disease","volume":"27","author":"Lopez","year":"2007","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.111.187443_bib17","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.neuropharm.2008.06.038","article-title":"Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats","volume":"55","author":"Lopez","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.111.187443_bib18","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.nbd.2004.01.007","article-title":"A model of l-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function","volume":"16","author":"Lundblad","year":"2004","journal-title":"Neurobiol Dis"},{"key":"10.1124\/jpet.111.187443_bib19","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0028-3908(03)00271-5","article-title":"(\u2212)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection","volume":"45","author":"Maj","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.111.187443_bib20","doi-asserted-by":"crossref","first-page":"13668","DOI":"10.1073\/pnas.1835724100","article-title":"Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson\u2019s disease treatment","volume":"100","author":"Marino","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1124\/jpet.111.187443_bib21","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0014-2999(77)90256-4","article-title":"Supersensitivity to apomorphine following destruction of the ascending dopamine neurons: quantification using the rotational model","volume":"41","author":"Marshall","year":"1977","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.111.187443_bib22","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.neuroscience.2003.08.032","article-title":"Activation of group III metabotropic glutamate receptors presynaptically reduces both GABAergic and glutamatergic transmission in the rat globus pallidus","volume":"122","author":"Matsui","year":"2003","journal-title":"Neuroscience"},{"key":"10.1124\/jpet.111.187443_bib23","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/978-3-540-89615-9_18","article-title":"Adenosine A2A receptors and Parkinson\u2019s disease","volume":"193","author":"Morelli","year":"2009","journal-title":"Handb Exp Pharmacol"},{"key":"10.1124\/jpet.111.187443_bib24","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev.pharmtox.011008.145533","article-title":"Metabotropic glutamate receptors: physiology, pharmacology, and disease","volume":"50","author":"Niswender","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/jpet.111.187443_bib25","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1124\/mol.108.049551","article-title":"Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4","volume":"74","author":"Niswender","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.111.187443_bib26","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1177\/1073858404266776","article-title":"Cognitive dysfunction in Parkinson\u2019s disease: the role of frontostriatal circuitry","volume":"10","author":"Owen","year":"2004","journal-title":"Neuroscientist"},{"key":"10.1124\/jpet.111.187443_bib27","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0022-3565(25)20316-0","article-title":"Inhibition of monoamine oxidase-B by (\u2212)-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum","volume":"258","author":"Paterson","year":"1991","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.187443_bib28","series-title":"The Rat Brain in Stereotoxic Coordinates","author":"Paxinos","year":"2007"},{"key":"10.1124\/jpet.111.187443_bib29","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.neuropharm.2009.11.012","article-title":"A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug","volume":"58","author":"Pinna","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.111.187443_bib30","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0028-3908(96)00177-3","article-title":"Activation of group III metabotropic glutamate receptors depresses glutamatergic transmission at corticostriatal synapse","volume":"36","author":"Pisani","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.111.187443_bib31","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.disamonth.2007.05.002","article-title":"Current pharmacotherapeutic treatment options in Parkinson\u2019s disease","volume":"53","author":"Rezak","year":"2007","journal-title":"Dis Mon"},{"key":"10.1124\/jpet.111.187443_bib32","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0028-3908(00)00005-8","article-title":"CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury","volume":"39","author":"Schallert","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.111.187443_bib33","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1021\/jm070262c","article-title":"Synthesis and biological evaluation of 1-amino-2-phosphonomethylcyclopropanecarboxylic acids, new group III metabotropic glutamate receptor agonists","volume":"50","author":"Sibille","year":"2007","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.111.187443_bib34","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1021\/jm070623o","article-title":"Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy","volume":"51","author":"Slee","year":"2008","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.111.187443_bib35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/WNF.0b013e318065b088","article-title":"Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia","volume":"31","author":"Stacy","year":"2008","journal-title":"Clin Neuropharmacol"},{"key":"10.1124\/jpet.111.187443_bib36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/978-1-4419-6306-2_17","article-title":"Combination analysis","volume":"678","author":"Tallarida","year":"2010","journal-title":"Adv Exp Med Biol"},{"key":"10.1124\/jpet.111.187443_bib37","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.neuropharm.2007.08.006","article-title":"Interaction of A2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission","volume":"53","author":"Tozzi","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.111.187443_bib38","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1124\/jpet.106.109207","article-title":"The dopamine agonist piribedil with l-DOPA improves attentional dysfunction: relevance for Parkinson\u2019s disease","volume":"319","author":"Turle-Lorenzo","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.187443_bib39","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1124\/jpet.104.080481","article-title":"Group III metabotropic glutamate-receptor-mediated modulation of excitatory transmission in rodent substantia nigra pars compacta dopamine neurons","volume":"313","author":"Valenti","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.187443_bib40","doi-asserted-by":"crossref","first-page":"7218","DOI":"10.1523\/JNEUROSCI.23-18-07218.2003","article-title":"Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse","volume":"23","author":"Valenti","year":"2003","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.111.187443_bib41","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00213-008-1214-8","article-title":"The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates","volume":"200","author":"Varty","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.111.187443_bib42","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jpba.2008.05.011","article-title":"An automated, high-throughput, 384-well cytochrome P450 cocktail IC50 assay using a rapid resolution LC-MS\/MS end-point","volume":"48","author":"Youdim","year":"2008","journal-title":"J Pharm Biomed Anal"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524467311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524467311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.111.187443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T02:42:04Z","timestamp":1740019324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524467311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0022356524467311"],"URL":"https:\/\/doi.org\/10.1124\/jpet.111.187443","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Metabotropic Glutamate Receptor 4-Positive Allosteric Modulator VU0364770 Produces Efficacy Alone and in Combination with l-DOPA or an Adenosine 2A Antagonist in Preclinical Rodent Models of Parkinson\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.111.187443","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2012 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}